Trehalase (EC 3.2.1.28) acts specifically on the α,α-glycosidic bond of trehalose, releasing 2 mol of D-glucose per mol of substrate. Because trehalose is non-reducing, the conversion generates reducing equivalents only after cleavage, which makes the enzyme a decisive upstream module in enzymatic sugar accounting rather than a bulk industrial catalyst. Commercial trehalase preparations are typically supplied as ammonium sulfate suspensions or lyophilized powders with recommended storage at 2–8°C; repeated freeze-thaw cycling causes irreversible loss of quaternary activity. In analytical systems, the trehalase cleavage step is followed by hexokinase-catalyzed phosphorylation and glucose-6-phosphate dehydrogenase-mediated NAD⁺ reduction, producing NADH absorbance at 340 nm. Method linearity, repeatability, and intermediate precision for this type of coupled assay are established under the precision design of ISO 5725-2:2019 when the method is transferred between laboratories. The operational boundary of the enzyme is narrow at high glucose background concentrations because the difference calculation between post-hydrolysis and pre-hydrolysis glucose values collapses when free glucose exceeds approximately 10 times the trehalose concentration.

Carbohydrate-modified food quality control relies on trehalase cleavage to determine trehalose additions in bakery fillings, extruded cereal binders, mushroom concentrates, and plant-based protein formulations. A sample extract is split into two aliquots: the first is treated with trehalase at 37°C for 15–20 min in 50 mmol/L MES or PIPES buffer at approximately pH 6.5, and the second is incubated with buffer only. After treatment, both aliquots are deproteinized with Carrez reagents or perchloric acid to remove turbidity and enzyme protein. The liberated glucose is then quantified by the hexokinase/glucose-6-phosphate dehydrogenase system, with absorbance recorded at 340 nm against a four-point glucose calibration prepared in the same matrix. Trehalose concentration is calculated as 0.5 × (post-hydrolysis glucose − pre-hydrolysis glucose) and corrected for recovery. Because trehalase from some sources contains trace α-glucosidase activity, a specificity challenge with maltose, sucrose, and isomaltulose at expected matrix levels must be included during method validation; any drift above the accepted blank indicates contaminated enzyme lots or insufficient pH control. In low-moisture extruded matrices, high-temperature processing can produce Maillard-derived compounds that absorb at 340 nm and bias the NADH reading; this is addressed by running a sample blank without the coupling reagents and subtracting its absorbance. The limit of quantification for the coupled assay is matrix-dependent but typically falls in the range of 5–20 mg/kg when a 1 g sample is extracted into 50 mL and a 0.1 mL aliquot is assayed.

Fermentation Broth Residual Trehalose: A Source-Specific Blanking Problem

Yeast producers quantify intracellular trehalose as a stress marker during high-gravity brewing and baker's yeast manufacturing. The cell pellet is extracted with 80% ethanol at 80°C for 30 min, followed by evaporation and reconstitution in a low-ionic-strength buffer. Trehalase treatment of the reconstituted extract enables quantification of trehalose independently of glycogen-derived glucose when the enzyme preparation is free of amyloglucosidase. Because fermentation broth contains residual maltose, maltotriose, and sucrose, the hexokinase reaction does not detect these disaccharides; however, contaminating α-glucosidase in the trehalase preparation can hydrolyse maltose to glucose and produce falsely elevated trehalose values. Therefore, the enzyme lot must be challenged with 2 g/L maltose under the same incubation conditions; a glucose increase greater than 0.5% of the maltose molar amount indicates unacceptable side activity. In baker's yeast manufacturing, trehalose contents typically range from less than 1% dry weight in early log-phase cells to above 10% dry weight after carbon limitation or heat shock, so the trehalase-based method must span two orders of magnitude. The lower end of that range requires a preconcentration step because the coupled assay loses precision when net absorbance differences are below 0.100 AU. Published data for exact lot-to-lot variance in commercial trehalase side activities in yeast broth is limited; users must therefore conduct source-specific blanking for each supplier lot rather than relying on generic acceptance criteria. The enzyme raw material should be accompanied by a certificate attesting compliance with the JECFA General Specifications for Enzyme Preparations (FAO Food and Nutrition Paper 52, Vol. 4) for absence of Salmonella and Escherichia coli.

What Interference Pattern Dominates Urinary Trehalose Clearance Assays?

Clinical research protocols that use the dual-sugar permeability test generate urine samples in which trehalose must be measured by trehalase cleavage because chromatographic separation of trehalose from lactose and glucose is laborious. After timed urine collection, samples are acidified or heated to inhibit endogenous trehalase activity, then adjusted to pH 6.5 before exogenous trehalase addition. The dominant interference is glucose, especially in diabetic patients or in samples collected after meals, because urinary glucose can exceed trehalose concentration by a factor of 50 or more. The split-aliquot differential measurement then becomes statistically unstable, and the propagated uncertainty exceeds 20% relative standard deviation unless the urine is diluted to bring free glucose into the linear range of the hexokinase assay. Creatinine normalization is performed on an aliquot using the Jaffe method or enzymatic creatinine testing, and the detection capability parameters are evaluated according to CLSI EP17-A2. Trehalase inhibitor validamycin A can be used as a specificity control; its addition suppresses trehalose cleavage and provides a matrix-specific negative control. Endogenous urinary trehalase activity must be fully denatured before the exogenous enzyme step because any residual activity shifts the pre-hydrolysis glucose baseline during the incubation period.

Lyophilised Drug Product Residual Excipient Cleavage

The lyoprotectant function of trehalose in freeze-dried monoclonal antibody formulations and vaccine matrices creates a quality control requirement for trehalose content verification. A trehalase-based enzymatic step converts trehalose to glucose before high-performance anion-exchange chromatography with pulsed amperometric detection, allowing separation from sucrose, mannitol, glycine, and histidine. The use of trehalase avoids the poor specificity of refractive index detection and the coelution of trehalose with lactose or maltose on standard reversed-phase columns. Method validation follows ICH Q2(R1) for specificity, linearity, accuracy, precision, and range; system suitability is assessed under USP <621> and analytical instrument qualification under USP <1058>. The enzyme reaction must be quenched by heating to 80°C for 5 min before injection to prevent in-column formation of glucose from residual trehalose. If the formulation contains sorbitol or mannitol, the absence of contaminating mannitol dehydrogenase or α-glucosidase in the trehalase lot is critical because a false glucose signal changes trehalose recovery. Trehalase incubation is typically performed at 37°C for 30 min in 25 mmol/L phosphate buffer pH 6.8, but the exact time must be confirmed by a hydrolysis efficiency curve because lyophilized excipient matrices can contain citrate residuals that chelate divalent cations in the hexokinase coupling step, reducing NADH formation. Published data for this specific configuration in high-concentration antibody formulations is limited; pharmaceutical QC laboratories therefore establish formulation-specific tolerance intervals rather than adopting vendor-supplied conversion factors.

Spodoptera frugiperda and Trichoplusia ni cell lines accumulate and release trehalose under serum-free conditions; monitoring of this metabolite in baculovirus expression systems requires trehalose quantification in clarified supernatant and cell pellets. The trehalase-based split-aliquot assay is applied after cell pellet disruption in 10 mmol/L Tris-HCl pH 7.0 with 0.1% Triton X-100, followed by heat inactivation of endogenous acid trehalase at 70°C for 10 min. Because cell culture media often contain glucose at 5–20 mmol/L, the free-glucose background is high relative to trehalose, and the differential measurement requires either a glucose-depletion step, a high-specificity glucose biosensor, or a chromatographic finish. In this matrix, glucose oxidase-peroxidase chromogenic end-points are vulnerable to peroxide scavengers in serum-free supplements, and the hexokinase method is preferred because it does not rely on peroxidase. The trehalase reaction itself is inhibited by trehalase inhibitors in hydrolysates of plant-derived media supplements if those hydrolysates have not been ultrafiltered below 10 kDa; this is a production-scale concern because hydrolysate lot changes can shift trehalose recovery by more than 15% without any change in enzyme activity. The enzyme raw material should be certified free of protease activity because baculovirus harvests may contain residual trypsin-like proteases from serum-free adaptation that can degrade trehalase during the 20 min incubation.

When Automated Flow Injection Analysis Requires Immobilised Trehalase Reactors

Automation of trehalose measurement in high-throughput quality analytical lines is achieved by immobilising trehalase onto controlled pore glass or methacrylate beads for use in flow injection analysis and sequential injection systems. The immobilization strategy converts the soluble enzyme into a reusable reactor, but the pH optimum shifts by approximately 0.5–1.0 pH units depending on the carrier charge. A cationic methacrylate carrier stabilizes the enzyme at pH 5.5, whereas controlled pore glass often requires pH 6.8–7.2 for optimal recovery. The carrier surface must be activated with glutaraldehyde or carbodiimide under conditions that preserve the catalytic histidine and aspartate residues in the active cleft. After immobilization, the reactor is installed in a temperature-controlled jacket at 30–37°C, and substrate is passed through at a flow rate that yields a residence time of 2–5 min. Backpressure and protein leaching are the dominant operational failure modes; leaching can be monitored by Bradford assay of the eluate, and a loss of more than 5% reactor activity after 50 cycles indicates insufficient cross-linking or excessive shear. Because published data for long-term trehalase reactor stability under process conditions is limited, qualification requires a site-specific reactor-performance log with control charts rather than reliance on supplier stability claims. The device qualification and thermostatic accuracy are documented under USP <1058>, and the fluidic precision is verified according to ISO 8655-6:2022 for piston-operated volumetric apparatus.